Alexandr S. Pristupa
Research Subjects
Alexandr S. Pristupa has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra V. Solov'YEva
Ryazan State Medical University named after academician I.P. Pavlov
2 shared publications - Sergey G. Bolotin
Regional Clinical Hospital
2 shared publications Angela Howes
Janssen Research & Development, High Wycombe, United Kingdom
1 shared publication- Asher Chanan-Khan
Mayo Clinic School of Medicine, New York University, New York, USA
1 shared publication - Charles E. Phelps
University of Rochester, Rochester, NY, USA
1 shared publication - Dina Ben Yehuda
Department of Hematology, Hadassah Medical Center, Jerusalem 9112001, Israel
1 shared publication
Latest Publications
- Open Access
- 16 June 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
Risk factors associated with mortality in patients with multiple myeloma
Introduction. According to foreign authors some laboratory markers and comorbidity are independent predictors of death in multiple myeloma (MM).Aim. To identify risk factors associated with mortality in patients with MM.Materials and methods. A retrospective analysis of 149 medical records of patients of the hematology department of the Regional Clinical Hospital with a diagnosis of multiple myeloma was carried out. The patients are divided into two groups depending on the clinical outcome: the 1st group includes 90 living patients; the 2nd group includes 59 patients whose death occurred in the hospital during the period from 2010–2019. Of the 149 patients: 87 women (58%), 62 men (42%). The mean age of the patients was 65.7 ± 8.7 years. The clinical, demographic and laboratory indicators of the groups were analyzed, and comorbidity was assessed using the Charlson index.Results. In the 1st group of patients, there were 35 men (39%) and 55 women (61%). The ratio of men to women is 1:1.6. The mean age in this group is 67 ± 9.1 years. The 2nd group is represented by 27 (46%) men, 32 (54%) women. The mean age was 63.7 ± 7.6 years. In the 1st group of patients, all patients were diagnosed with stage III disease, with most patients in the subgroup associated with renal dysfunction (p = 0.002). Anaemia and markers of renal damage were more frequent in the group of deceased patients (p < 0.001, p = 0.002, respectively). Comparative analysis of laboratory indicators showed that in the haemogram of the group of living patients, the level of erythrocytes, haemoglobin, platelets was significantly higher than in group 2 (p < 0.05); the level of creatinine, urea was 1.8 times higher in the group of deceased patients than in the group of living patients (p < 0.05). Chronic heart failure was statistically significantly more common in the deceased group than in the living group (22% vs. 7.8%, p = 0.025). The incidence of pneumonia was higher in the deceased group than in the 1st group (p < 0.001).Conclusion. Risk factors associated with mortality include manifestations of MM such as anaemia, thrombocytopenia, renal dysfunction and late diagnosis at stage III of the disease. Chronic heart failure, as a complication of cardiovascular disease, is a risk factor for adverse outcome. Comorbidity, infectious diseases (pneumonia) are associated with a worse prognosis, probably due to poorer tolerability of standard therapy.
- 16 June 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
Open AccessRisk factors associated with mortality in patients with multiple myeloma
Introduction. According to foreign authors some laboratory markers and comorbidity are independent predictors of death in multiple myeloma (MM).Aim. To identify risk factors associated with mortality in patients with MM.Materials and methods. A retrospective analysis of 149 medical records of patients of the hematology department of the Regional Clinical Hospital with a diagnosis of multiple myeloma was carried out. The patients are divided into two groups depending on the clinical outcome: the 1st group includes 90 living patients; the 2nd group includes 59 patients whose death occurred in the hospital during the period from 2010–2019. Of the 149 patients: 87 women (58%), 62 men (42%). The mean age of the patients was 65.7 ± 8.7 years. The clinical, demographic and laboratory indicators of the groups were analyzed, and comorbidity was assessed using the Charlson index.Results. In the 1st group of patients, there were 35 men (39%) and 55 women (61%). The ratio of men to women is 1:1.6. The mean age in this group is 67 ± 9.1 years. The 2nd group is represented by 27 (46%) men, 32 (54%) women. The mean age was 63.7 ± 7.6 years. In the 1st group of patients, all patients were diagnosed with stage III disease, with most patients in the subgroup associated with renal dysfunction (p = 0.002). Anaemia and markers of renal damage were more frequent in the group of deceased patients (p < 0.001, p = 0.002, respectively). Comparative analysis of laboratory indicators showed that in the haemogram of the group of living patients, the level of erythrocytes, haemoglobin, platelets was significantly higher than in group 2 (p < 0.05); the level of creatinine, urea was 1.8 times higher in the group of deceased patients than in the group of living patients (p < 0.05). Chronic heart failure was statistically significantly more common in the deceased group than in the living group (22% vs. 7.8%, p = 0.025). The incidence of pneumonia was higher in the deceased group than in the 1st group (p < 0.001).Conclusion. Risk factors associated with mortality include manifestations of MM such as anaemia, thrombocytopenia, renal dysfunction and late diagnosis at stage III of the disease. Chronic heart failure, as a complication of cardiovascular disease, is a risk factor for adverse outcome. Comorbidity, infectious diseases (pneumonia) are associated with a worse prognosis, probably due to poorer tolerability of standard therapy.
- 28 December 2022
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 30 (4) , 547-554
Analysis of Recorded Morbidity, Prevalence and Hospital Mortality of Patients with Symptomatic Multiple Myeloma in the Ryazan Region for 10 Years
INTRODUCTION: Multiple myeloma (MM) is a disease whose substrate is plasma cells; it is characterized by the production of monoclonal immunoglobulin. Epidemiology of MM in Russia is insufficiently studied. Of interest is a study of dynamics of the main epidemiological parameters of multiple myeloma in the context of a poor epidemiological prognosis for oncological diseases in the Russian Federation and in the world in general. AIM: To analyze the main epidemiological parameters of symptomatic MM in the Ryazan region for 10 years (20102019). MATERIALS AND METHODS: A total of 343 medical records of patients with symptomatic MM were analyzed, of them 146 men (age median 65 years), 197 women (age median 64 years). The patients underwent inpatient treatment in the hematology and chemotherapy department of Ryazan Regional Clinical Hospital from 2010 to 2019. The epidemiological analysis consisted in evaluation of the parameters of the registered morbidity, prevalence and hospital mortality. The criterion for inclusion in the study was the existence of symptomatic MM in the patient. For statistical processing, Microsoft information and analytical system, Office package was used. RESULTS: The highest amount of new cases of MM were identified in 2018 (4.19 per 100,000 population), the lowest in 2012 (1.83 per 100,000 population). In the analyzed period, the number of cases of newly diagnosed MM per year increased by 30.3%. Most patients at the time of diagnosis were in the age group of 6069 years. Morbidity with MM in the age group of 3049 years was comparable in men and women, however, among the patients 50 years women predominated. Over 10 years, the index of MM prevalence in the Ryazan region increased 1.43 times: from 6.71 to 9.6 per 100,000 population, index of hospital mortality from 1.4% to 3.3%. CONCLUSION: The growth of the registered mortality and prevalence of MM in the Ryazan region in 20102019 was identified, which corresponds to the dynamics in other regions of the Russian Federation. Also, during the analyzed period, an increase in hospital mortality of patients with MM was observed in the region.
- 28 December 2022
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 30 (4) , 547-554
Analysis of Recorded Morbidity, Prevalence and Hospital Mortality of Patients with Symptomatic Multiple Myeloma in the Ryazan Region for 10 Years
INTRODUCTION: Multiple myeloma (MM) is a disease whose substrate is plasma cells; it is characterized by the production of monoclonal immunoglobulin. Epidemiology of MM in Russia is insufficiently studied. Of interest is a study of dynamics of the main epidemiological parameters of multiple myeloma in the context of a poor epidemiological prognosis for oncological diseases in the Russian Federation and in the world in general. AIM: To analyze the main epidemiological parameters of symptomatic MM in the Ryazan region for 10 years (20102019). MATERIALS AND METHODS: A total of 343 medical records of patients with symptomatic MM were analyzed, of them 146 men (age median 65 years), 197 women (age median 64 years). The patients underwent inpatient treatment in the hematology and chemotherapy department of Ryazan Regional Clinical Hospital from 2010 to 2019. The epidemiological analysis consisted in evaluation of the parameters of the registered morbidity, prevalence and hospital mortality. The criterion for inclusion in the study was the existence of symptomatic MM in the patient. For statistical processing, Microsoft information and analytical system, Office package was used. RESULTS: The highest amount of new cases of MM were identified in 2018 (4.19 per 100,000 population), the lowest in 2012 (1.83 per 100,000 population). In the analyzed period, the number of cases of newly diagnosed MM per year increased by 30.3%. Most patients at the time of diagnosis were in the age group of 6069 years. Morbidity with MM in the age group of 3049 years was comparable in men and women, however, among the patients 50 years women predominated. Over 10 years, the index of MM prevalence in the Ryazan region increased 1.43 times: from 6.71 to 9.6 per 100,000 population, index of hospital mortality from 1.4% to 3.3%. CONCLUSION: The growth of the registered mortality and prevalence of MM in the Ryazan region in 20102019 was identified, which corresponds to the dynamics in other regions of the Russian Federation. Also, during the analyzed period, an increase in hospital mortality of patients with MM was observed in the region.
- Open Access
- 2 December 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (22) , 4397
Early Changes in Circulating T-Cell Immune Profiles in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Data from the Phase 3, Double-Blind HELIOS Trial
Introduction Ibrutinib is a first-in-class, once-daily, oral, covalent inhibitor of Bruton's tyrosine kinase (BTK) that as a single agent has significantly improved overall survival in patients (pts) with both treatment naïve and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In the phase 3 HELIOS trial, the addition of ibrutinib to bendamustine + rituximab (BR) resulted in an 80% reduction in disease progression or death (HR, 0.203, 95% CI, 0.150-0.276; p < 0.0001) and confirmed for the first time, in a randomized setting, the benefit of ibrutinib-based therapy compared with standard chemoimmunotherapy in previously treated pts (Chanan-Khan, et al. Lancet Oncol. 2016;17(2):200-11). Independent Review Committee assessed progression-free survival (PFS) at 18 months was 79% (95% CI: 73%-83%) in the ibrutinib +BR (I+BR) arm and 24% (95% CI: 18%-31%) in the placebo + BR (P+BR) arm. While the activity of ibrutinib is primarily in B-cells where it inhibits BTK-dependent survival pathways, it may also have significant effects on the immune system by exerting an effect on T-cells (by inhibition of interleukin-2-inducible kinase and related shift from Th2 to Th1-based immunity, which in turn affects Treg and Th17 activity) and via normalization of immune function, thus affecting tumor response. Here, we report changes in circulating T-cell immunophenotypes in a subset of pts treated with either I+BR or P+BR in the HELIOS study. Methods HELIOS is a randomized, double-blind, placebo-controlled, phase 3 study. Pts with active CLL/SLL following ≥ 1 prior therapy were randomized 1:1 to receive BR (≤ 6 cycles) with either ibrutinib (420 mg daily; n = 289) or placebo (n = 289). Pts with del17p (> 20% of cells) were excluded. Peripheral blood was collected at the start of the study, at Cycle 1, Day 15 (C1D15) and at the end of treatment/time of progressive disease (EOT/PD). From these samples, peripheral blood mononuclear cells (PBMC) were separated and cryopreserved. PBMC were subjected to flow-cytometric analysis of T-cell subsets including CD4, CD8 and markers indicative of Treg cells (CD25+CD127low) and Th17 cells (CCR4+CCR6+). In addition, expression of T-cell checkpoints ICOS, PD-1 and OX-40 by CD4 and CD8 cells were evaluated as an indicator of cell activation or activation/exhaustion. The findings from the HELIOS study reported here are based on analysis of paired samples (C1D1 and C1D15) of 29 CLL cases from the I+BR arm and 22 cases from the P+BR arm. The Mann-Whitney U test was applied to determine the significance of the differences in each of T-cell subtype between the two arms. Results Overall, there was a net increase in the percentage of CD3+ cells with treatment in both the I+BR-treated pts and P+BR-treated pts, which was observed as early as Day 15 (+12.0% and +11.42% of total lymphocytes, respectively, at C1D15 compared with C1D1; Figure 1). The EOT/PD samples showed a continued increase in the percentage of CD3+ cells in the I+BR pts, the majority of whom (11/12) were responders, while the opposite trend was observed in the P+BR patients (8/21 responders). Focusing on the early changes in the analysis of T-cell subsets, a pronounced decrease in the percentage of Th17 CD4+ cells was noted in the I+BR pts (mean: -2.49%) but in the P+BR pts, an increase of this subset (mean: +2.66%) was observed (p = 0.011; Figure 2). When comparing other CD4+ subsets, decreases in Treg cells were seen in both pt groups, with a corresponding increase in the T-cell activation marker ICOS. Less significant changes were observed in the other T-cell markers studied, however, a trend to increased PD-1 was seen in the P+BR pts but not in the I+BR pts. The safety profile in these pts was consistent with previous reports for the study. Conclusions These results suggest that the addition of ibrutinib to BR helped restore T-cell proportions in this subset of cases and it is noteworthy that this effect was visible even within 15 days of initiation of therapy. Data from the I+BR pts showed a pronounced decrease in the percentage of Th17 CD4+ cells, which are primarily pro-tumorigenic but may sometimes have anti-tumor effects, and a concomitant decrease in the percentage of Treg cells, which may explain the overall increase in T-cell activation. These findings may also be related to the observed increase in PFS with the addition of ibrutinib to BR reported in the trial.
- 2 December 2016
- Published by American Society of Hematology in Blood
- Vol. 128 (22) , 4397
Open AccessEarly Changes in Circulating T-Cell Immune Profiles in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Data from the Phase 3, Double-Blind HELIOS Trial
Introduction Ibrutinib is a first-in-class, once-daily, oral, covalent inhibitor of Bruton's tyrosine kinase (BTK) that as a single agent has significantly improved overall survival in patients (pts) with both treatment naïve and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In the phase 3 HELIOS trial, the addition of ibrutinib to bendamustine + rituximab (BR) resulted in an 80% reduction in disease progression or death (HR, 0.203, 95% CI, 0.150-0.276; p < 0.0001) and confirmed for the first time, in a randomized setting, the benefit of ibrutinib-based therapy compared with standard chemoimmunotherapy in previously treated pts (Chanan-Khan, et al. Lancet Oncol. 2016;17(2):200-11). Independent Review Committee assessed progression-free survival (PFS) at 18 months was 79% (95% CI: 73%-83%) in the ibrutinib +BR (I+BR) arm and 24% (95% CI: 18%-31%) in the placebo + BR (P+BR) arm. While the activity of ibrutinib is primarily in B-cells where it inhibits BTK-dependent survival pathways, it may also have significant effects on the immune system by exerting an effect on T-cells (by inhibition of interleukin-2-inducible kinase and related shift from Th2 to Th1-based immunity, which in turn affects Treg and Th17 activity) and via normalization of immune function, thus affecting tumor response. Here, we report changes in circulating T-cell immunophenotypes in a subset of pts treated with either I+BR or P+BR in the HELIOS study. Methods HELIOS is a randomized, double-blind, placebo-controlled, phase 3 study. Pts with active CLL/SLL following ≥ 1 prior therapy were randomized 1:1 to receive BR (≤ 6 cycles) with either ibrutinib (420 mg daily; n = 289) or placebo (n = 289). Pts with del17p (> 20% of cells) were excluded. Peripheral blood was collected at the start of the study, at Cycle 1, Day 15 (C1D15) and at the end of treatment/time of progressive disease (EOT/PD). From these samples, peripheral blood mononuclear cells (PBMC) were separated and cryopreserved. PBMC were subjected to flow-cytometric analysis of T-cell subsets including CD4, CD8 and markers indicative of Treg cells (CD25+CD127low) and Th17 cells (CCR4+CCR6+). In addition, expression of T-cell checkpoints ICOS, PD-1 and OX-40 by CD4 and CD8 cells were evaluated as an indicator of cell activation or activation/exhaustion. The findings from the HELIOS study reported here are based on analysis of paired samples (C1D1 and C1D15) of 29 CLL cases from the I+BR arm and 22 cases from the P+BR arm. The Mann-Whitney U test was applied to determine the significance of the differences in each of T-cell subtype between the two arms. Results Overall, there was a net increase in the percentage of CD3+ cells with treatment in both the I+BR-treated pts and P+BR-treated pts, which was observed as early as Day 15 (+12.0% and +11.42% of total lymphocytes, respectively, at C1D15 compared with C1D1; Figure 1). The EOT/PD samples showed a continued increase in the percentage of CD3+ cells in the I+BR pts, the majority of whom (11/12) were responders, while the opposite trend was observed in the P+BR patients (8/21 responders). Focusing on the early changes in the analysis of T-cell subsets, a pronounced decrease in the percentage of Th17 CD4+ cells was noted in the I+BR pts (mean: -2.49%) but in the P+BR pts, an increase of this subset (mean: +2.66%) was observed (p = 0.011; Figure 2). When comparing other CD4+ subsets, decreases in Treg cells were seen in both pt groups, with a corresponding increase in the T-cell activation marker ICOS. Less significant changes were observed in the other T-cell markers studied, however, a trend to increased PD-1 was seen in the P+BR pts but not in the I+BR pts. The safety profile in these pts was consistent with previous reports for the study. Conclusions These results suggest that the addition of ibrutinib to BR helped restore T-cell proportions in this subset of cases and it is noteworthy that this effect was visible even within 15 days of initiation of therapy. Data from the I+BR pts showed a pronounced decrease in the percentage of Th17 CD4+ cells, which are primarily pro-tumorigenic but may sometimes have anti-tumor effects, and a concomitant decrease in the percentage of Treg cells, which may explain the overall increase in T-cell activation. These findings may also be related to the observed increase in PFS with the addition of ibrutinib to BR reported in the trial.